25th November 2025
07:00 [PST] 10:00 [EST] 15:00 [GMT]
Turn complexity into clarity. Learn how method development unlocks accurate, robust LC–MS/MS bioanalysis for oligonucleotide therapeutics.
Oligonucleotide therapies are rapidly moving from promise to reality, but analyzing them isn’t straightforward. Their unique structures, modifications and behavior in biological matrices create hurdles at every stage of the workflow, from sample prep to quantitation. LC–MS/MS provides a powerful path forward, but only with carefully optimized methods that ensure sensitivity, accuracy and robustness. In this webinar, experts share key lessons from real-world method development, highlighting common pitfalls, practical strategies and purpose-built tools that can help you generate dependable data with confidence.
What will you learn?
- Understand the key challenges that make oligonucleotide bioanalysis complex
- Explore proven strategies to overcome sensitivity and matrix hurdles
- Observe how purpose-built tools deliver accurate, sensitive and robust bioanalytical methods
Marian TwohigConsulting Scientist, LC–MS Portfolio
Waters Corporation
Marian has over 20 years of experience supporting quantitative and qualitative applications in the pharmaceutical, food and environmental and materials science industries. She works as a Principal Scientist for Waters Corporation where she has previously held several Senior Scientist positions. Currently, the focus of Marian’s work involves the development of quantitative analytical methods to meet the needs of the pharmaceutical industry. She is particularly interested in chromatographic separations, and the application of combining low- and high-resolution mass spectral data with other chemical information for the identification of unknown chemical entities. Marian holds a PhD in Analytical Chemistry from Munster Technological University (formerly CIT; Cork, Ireland).
